# US 11,077,110 B2 · Compositions and methods for treating and preventing metabolic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,110 B2
- Document ID: US11077110B2
- Status: Granted
- Kind: B2
- Application number: 16/086,143
- Filed: 2017-03-17
- Published: 2019-06-27
- Granted: 2021-08-03
- Earliest claimed: 2016-03-18
- Assignees: Tufts Medical Center, Inc.
- Applicants: Tufts Medical Center
- Inventors: Miaofen G. Hu
- Web page: https://patentgrep.com/patent/US11077110B2

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A01K 67/0276: Knock-out vertebrates
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12Y 207/11022: Cyclin-dependent kinase (2.7.11.22)
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A01K 2227/105: Murine
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are compositions and methods for treating or preventing metabolic disorders. In particular, provided herein are compositions, methods, and uses of Cyclin-dependent Kinase 6 (CDK6) inhibitors for treating and preventing metabolic diseases (e.g., type II diabetes, obesity, metabolic syndrome, elevated blood pressure, cardiovascular diseases, elevated fasting plasma glucose, and high serum triglycerides).

## Claims

### Claim 1

A method of treating metabolic disease in a subject diagnosed with a metabolic disease selected from the group consisting of type II diabetes, obesity, metabolic syndrome, elevated blood pressure, cardiovascular diseases, elevated fasting plasma glucose, and high serum triglycerides, comprising:
administering a CDK6 inhibitor to said subject,
wherein said administering reduces one or more symptoms of said metabolic disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein said CDK6 inhibitor is selected from the group consisting of a nucleic acid, a small molecule, a peptide, and an antibody.

### Claim 3 (depends on 2)

The method of claim 2, wherein said CDK6 inhibitor is a small molecule.

### Claim 4 (depends on 3)

The method of claim 3, wherein said small molecule is selected from the group consisting of PD0332991, LEE011, AT7519, JNJ-7706621, P276-00, and their pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said administering converts white fat to brown fat in said subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject is overweight or obese.

### Claim 7 (depends on 1)

The method of claim 1, wherein said subject is not overweight or obese.

### Claim 8 (depends on 1)

The method of claim 1, wherein said subject exhibits symptoms of said metabolic disease.

### Claim 9 (depends on 1)

The method of claim 1, wherein said subject does not exhibit symptoms of said metabolic disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein said CDK6 inhibitor is administered in combination with a second agent that treats a metabolic disease.

### Claim 11

A method of treating metabolic disease in a subject diagnosed with a metabolic disease selected from the group consisting of type II diabetes, obesity, metabolic syndrome, elevated blood pressure, cardiovascular diseases, elevated fasting plasma glucose, and high serum triglycerides, comprising:
administering a CDK6 inhibitor to said subject, wherein said CDK6 inhibitor is selected from the group consisting of PD0332991, LEE011, AT7519, JNJ-7706621, P276-00, and their pharmaceutically acceptable salts thereof,
wherein said administering reduces one or more symptoms of said metabolic disease.